Expertise in
1
conditions

Tom S. Waddell

Manchester, ENG, GB 
Expertise in
1
conditions
Manchester, ENG, GB 

Overview

Tom Waddell practices practicing medicine in Manchester, United Kingdom.

Mr. Waddell is highly rated in 1 condition, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Stomach Cancer, Colorectal Cancer, and Esophageal Cancer.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Manchester, ENG, United Kingdom
Other Locations
Oxford, ENG OX13PJ, United Kingdom
London, ENG, United Kingdom
Downs Road, Sutton Upon Derwent, ENG SM25PT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion
NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

53 Total Publications

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Journal: Cancer treatment and research communications
Published: May 03, 2026

Frequently Asked Questions about Tom S. Waddell

Is Tom S. Waddell a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Tom S. Waddell is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tom S. Waddell participate in research or clinical trials?

Yes. Tom S. Waddell has published 53 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Tom S. Waddell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Waddell's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile